Response to "Clinical relevance of venlafaxine ER for generalized anxiety disorder".

Save

This article relates to clinical relevance of venlafaxine ER for generalized anxiety disorder.

We have read with interest the commentary by Terao1 on our study.2 He highlighted possible arguments in the clinical meaningfulness of some scores and rates assessing the efficacy, impact of including patients with major depressive disorder (MDD) and excluding early placebo responders, and also pointed out a lack of discussion on discontinuation rate. In our response, we provide our perspectives on his concerns.

His primary concern was the degree of score differences between venlafaxine versus placebo in Hamilton Anxiety Rating Scale (HAM‐A) total score; however, the −1.9‐point difference observed between treatment groups was considered clinically meaningful as it aligns with results from past international studies of venlafaxine in patients with generalized anxiety disorder (GAD). The mean score difference (95% credible intervals) between treatment groups in prior studies was −2.69 (−3.50 to −1.89) according to Slee et al.,3 and our study result falls within these intervals, suggesting comparable efficacy. Without a minimally clinically important difference (MCID) for HAM‐A, we believe that comparing degree of improvement between groups is appropriate and referencing earlier studies represents a robust and clinically relevant approach to interpreting our results.

Additionally, changes in patient‐rated GAD‐7 scores demonstrated significantly greater improvement with venlafaxine compared to placebo. Similarly, changes in patient‐rated Sheehan Disability Scale (SDS) scores indicated improved functioning. Considering these additional measures, we believe that the improvement was perceptible to patients.

Similarly, Terao raised concerns on the clinical meaningfulness of the −2.1‐point difference between treatments in GAD‐7 score referencing the MCID determined by Toussaint et al.4; however, comparing the score difference between treatments with the MCID may be inappropriate as these measures serve different purposes. MCID reflects minimal clinically important change at the individual level,4 whereas the difference between treatments addresses statistical significance. Given that, comparing MCID with the change in GAD‐7 score in venlafaxine is considered a more appropriate approach.

The mean change in GAD‐7 score in venlafaxine was −7.9 points, which exceeds the MCID determined by Toussaint et al., indicating the improvement is acceptable to interpret as clinically meaningful.

We acknowledge that continuous measures provide more detail; however, remission rates based on HAM‐A thresholds have been used to examine efficacy in prior studies and are considered clinically meaningful.5 While binary outcomes (remission/non‐remission) may contain less granularity, they reflect a clear patient‐centered goal of remission. We agree that additional analyses using continuous outcomes have value and will consider this in future work.

A subgroup analysis for comorbid MDD status showed that HAM‐A scores numerically decreased after venlafaxine treatment in both subgroups (with and without comorbid MDD). However, superiority over placebo at Week 8 was statistically demonstrated only in patients with comorbid MDD (P = 0.018), not in those without (P = 0.075) (Fig. 1).

Nevertheless, secondary endpoints, specifically Clinical Global Impressions‐Severity of Illness (CGI‐S), GAD‐7, Zung Self‐Rating Anxiety Scale (Z‐SAS), and SDS scores, were statistically significantly improved compared with placebo in patients without comorbid MDD (Table S1). Improvements of these indices were not statistically significant in patients with comorbid MDD. These results suggest that patients with comorbid MDD experience clinically meaningful improvements in physician‐reported outcomes, whereas patients without comorbid MDD may experience clinically meaningful improvements in functional and patient‐reported outcomes.

It should be noted that any interpretation regarding the impact of MDD comorbidity should be considered exploratory and interpreted with caution because this study was not designed to evaluate whether comorbid MDD influences the efficacy of venlafaxine in GAD.

We acknowledged limitations from excluding early placebo responders, which may compromise external validity. As this was a clinical study, not a real‐world setting, it was designed to minimize variability and accurately estimate true pharmacological effect. We expect that external validity can be addressed through the long‐term extension study, results of which will be provided in subsequent publication.

Although discontinuation due to adverse events was higher in the venlafaxine group, observed events were consistent with the known safety profile. No severe or serious adverse events were reported in the venlafaxine group. Based on these findings, the higher discontinuation rate was not interpreted as indicative of a safety concern.

Whereas we recognize the limitations noted by Terao, we underscore that our study focused on providing true efficacy of venlafaxine in Japanese patients with GAD and early evidence of treatment effect and safety to provide timely insights using an appropriate approach. We believe the subsequent publication for the long‐term extension study can provide additional insights and answers to his concerns.

Supporting information

Related articles

PubMed

Resting-State EEG Spectral Power in Young Adults With Generalized Anxiety Disorder and Self-Reported Habitual Short Sleep: A Case-Control Study.

ABSTRACT Background Generalized anxiety disorder (GAD) and insufficient sleep frequently co‐occur during early adulthood, yet resting‐state electroencephalographic (EEG) evidence in this population remains limited. The present study aimed to characterize resting‐state EEG spectral power in young adults with GAD who also reported habitual short sleep, compared with healthy controls. Methods This exploratory case‐control study included 56 university students: 28 participants with GAD and self‐...

PubMed

Increased Serum TNF-α Levels Are Associated With Generalized Anxiety Disorder: A Case-Control Study.

ABSTRACT Background and Aims Generalized anxiety disorder (GAD) is a mental health disorder that affects many people in all aspects of their lives. It is characterized by persistent and excessive worry that the affected person finds difficult to control. The actual pathophysiology and mechanisms underlying GAD are still elusive. However, cytokines and cell signaling proteins are hypothesized to contribute to the pathogenesis of anxiety. The present study aimed to understand the association of...